Phase II evaluation of maytansine in patients with advanced head and neck cancer.
D001853:Bone Marrow / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008453:Maytansine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009420:Nervous System / Q000187:drug effects; D010078:Oxazines / Q000627:therapeutic use*
D010078:Oxazines; D008453:Maytansine